DETAILS, FICTION AND LINSITINIB THYROID EYE DISEASE

The LIDS demo fulfilled its Main endpoint with statistical significance to the 150mg BID dose. Linsitinib During this demo validated the security profile seen inside the prior oncology experiments and importantly shown a positive protection profile on key adverse activities (AEs) of desire with the IGF-1R target like Listening to impairment, hyperg